EUROCELL PLC (ECEL) — Preliminary financial results for the year ended 31 December 2025

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the EUROCELL PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And I'd now like to hand you over to Will Truman, CEO. Good morning, sir. Good morning. Welcome to EUROCELL's 2025 results presentation. I'm Will Truman, chief executive, and I'm with Michael Scott, who you who you all know as the CFO. This morning, we will follow a similar format to prior years in so much that I will give a brief overview, recognizing that I was appointed as CEO in February of this year. Mike will then cover the financial review. I will pick up the strategy update focusing on our commercial initiatives and then hand back Michael who will cover ESG, business effectiveness, and people first. I will then wrap up with a summary. As mentioned, I was appointed after the year end, but in overview, 2025 can be summarized as an improved performance over the prior year, principally by virtue of Alunet's inclusion in the group results. This shouldn't detract from the continued improvements made elsewhere but underlines the reality of the market within which EUROCELL operates. Group revenues improved 13% to $4.00 4,000,000 from $358,000,000 in the prior year. Operating profit for the year was 24,000,000 versus 23,000,000 in 2024. Good financial management is evidenced from th...